Neutral
●
GlobeNewsWire
●
vor 6 Monaten
CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 197,900 shares of Akebia's common stock on December 31, 2025. The options were granted as an inducement material to the employee...